Key result
Early in-hospital PCSK9 inhibition in AMI yields ~58-point higher LDL-C goal attainment and accelerates plaque regression.
Why the study?
Conventional statin-based stepwise titration in AMI often leaves patients above target lipid levels during the critical early risk window, prompting this review to synthesize the mechanisms and clinical evidence supporting extremely early in-hospital PCSK9 inhibitor initiation.
Does extremely early in-hospital initiation of PCSK9 inhibitors improve lipid target attainment, plaque stabilization, and cardiovascular outcomes compared to conventional stepwise statin titration in patients with acute myocardial infarction?
Does extremely early in-hospital initiation of PCSK9 inhibitors improve lipid target attainment, plaque stabilization, and cardiovascular outcomes compared to conventional stepwise statin titration in patients with acute myocardial infarction?
This review synthesizes pathophysiological and clinical trial evidence supporting a paradigm shift toward extremely early in-hospital initiation (within 0-72 hours) of PCSK9 inhibitors in acute myocardial infarction to achieve rapid LDL-C reduction, plaque stabilization, and pleiotropic vascular protection.
Answers are grounded in this paper and cite their sources.
May support early PCSK9i consideration in AMI; leaves open confirmation in outcome trials.
Historically, lipid management in acute myocardial infarction (AMI) has predominantly followed a statin-based stepwise titration strategy, causing many patients to miss their target lipid levels during the critical early risk window. Deeper research revealed that under the stress of acute ischemia and inflammatory microenvironments in AMI, PCSK9 exhibits a specific "extremely early burst", which impairs low-density lipoprotein cholesterol (LDL-C) clearance and directly drives pro-inflammatory macrophage polarization, endothelial barrier disruption, and microthrombosis through lipid-independent pathways. PCSK9 inhibitors achieve a dual blockade of this malignant pathological cascade by exerting strong lipid-dependent effects of lowering LDL-C and non-lipid pleiotropic effects of anti-inflammation and microcirculation protection. Recent clinical trials, including EVOPACS and EPIC-STEMI, substantiate that the extremely early in-hospital initiation of PCSK9 inhibitors (within 0-72 h of onset or periprocedurally during percutaneous coronary intervention) manifests a highly favorable safety profile concomitant with expedited lipid target attainment. Imaging studies, such as PACMAN-AMI, further demonstrated that early treatment can rapidly stabilize and promote the regression of vulnerable plaques, providing preliminary evidence that this strategy may reduce the short-term risk of recurrent cardiovascular events. Consequently, lipid-lowering pharmacotherapy is transitioning into a paradigm of "extremely early in-hospital initiation," effectively transcending conventional temporal therapeutic limitations. This review aims to systematically elucidate the stress-induced upregulation and pathophysiological mechanisms of PCSK9 within the acute AMI microenvironment, detail the dual interception mechanisms of PCSK9 inhibitors, and synthesize the clinical evidence base substantiating extremely early initiation over conventional therapeutic algorithms.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) conducted a review in Acute myocardial infarction. PCSK9 inhibitors (evolocumab, alirocumab) vs. Conventional stepwise statin-based titration or placebo plus statin was evaluated. Extremely early in-hospital PCSK9 inhibitor initiation (0-72 h) in AMI rapidly achieves LDL-C targets and promotes plaque regression.
Synapse has enriched 10 related papers. Consider them for comparative context: